{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T14:41:21Z","timestamp":1700318481601},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,10,30]],"date-time":"2002-10-30T00:00:00Z","timestamp":1035936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2002,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We studied 28 patients with accelerated phase chronic myelogenous leukemia (CML) who were enrolled on the Novartis expanded access study 114. Diagnosis of accel\u2010 erated phase CML was based on karyotypic evolution (n = 9) and hematologic criteria (n = 18). All patients were begun on 600 mg\/day of imatinib mesylate. Dose reductions to 400 mg\/day and then 300 mg\/day were prescribed for an absolute neutrophil count (ANC) of &lt;0.5\/\u03bcl or a platelet count of &lt;20,000\/\u03bcl. Twenty\u2010seven of the 28 patients continued treatment for a median of 34 weeks. Eleven patients developed thrombocytopenia following an average of 8.4 \u00b1 1.4 weeks of therapy. The onset of thrombocytopenia was associated with disease progression in one patient and a decline in bone marrow megakaryocytes in the other 10. Nine patients recovered to a platelet count of &gt;20,000\/\u03bcl after an average of 19.7 \u00b1 1.8 weeks. Patients who developed thrombocytopenia had a longer duration of disease (9.39 vs. 4.35 years; <jats:italic>P<\/jats:italic> &lt; 0.01) and were more likely to be diagnosed with accelerated phase CML by hematologic criteria. Hematologic responses in patients with and without thrombocytopenia were comparable; however, 31.3% of patients without thrombocytopenia had a complete cytogenetic response compared to none of those with thrombocytopenia. Grade III\u2013IV thrombocytopenia is common in accelerated phase CML and may be a marker for the inability to achieve cytogenetic response using single agent imatinib mesylate. Am. J. Hematol. 71:184\u2013190, 2002. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.10215","type":"journal-article","created":{"date-parts":[[2002,10,31]],"date-time":"2002-10-31T18:20:30Z","timestamp":1036088430000},"page":"184-190","source":"Crossref","is-referenced-by-count":6,"title":["Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia"],"prefix":"10.1002","volume":"71","author":[{"given":"Hendrik W.","family":"van Deventer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly S.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee R.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathe","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherie H.","family":"Dunphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,30]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161120-00007"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"issue":"1","key":"e_1_2_1_6_2","first-page":"845a","article-title":"Gleevec\/Glivec\u2122 (imatinib mesylate, STI\u2010571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: updated results of a phase II study","volume":"98","author":"Sawyers CL","year":"2001","journal-title":"Blood"},{"issue":"1","key":"e_1_2_1_7_2","first-page":"845a","article-title":"Gleevec (formerly STI571): an active drug in patients with Ph+ chronic myeloid leukemia in accelerated phase\u2014updated results of a phase II study","volume":"98","author":"Talpaz M","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_8_2","volume-title":"Clinical oncology","author":"Abeloff MD","year":"2000"},{"issue":"1","key":"e_1_2_1_9_2","first-page":"141a","article-title":"Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML AP) with imatinib mesylate (STI571)","volume":"98","author":"Kantarjian HM","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441404"},{"issue":"1","key":"e_1_2_1_11_2","first-page":"139a","article-title":"Risk factors for myelosuppression in chronic phase CML patients treated with imatinib mesylate (STI571)","volume":"98","author":"Mauro MJ","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.772"},{"key":"e_1_2_1_13_2","article-title":"The impact of clonal evolution on response to imatinib mesylate (Gleevec) in accelerated phase CML","volume":"98","author":"O'Dwyer ME","year":"2001","journal-title":"Blood"},{"issue":"2","key":"e_1_2_1_14_2","first-page":"s30","article-title":"Collection, analysis and transplantation of Ph\u2010negative blood precursor cells in chronic myeloid leukemia","volume":"10","author":"Frassoni F","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_15_2","first-page":"668","article-title":"Eradication of the Philadelphia chromosome\u2010positive clone and persistent restoration of normal polyclonal haemopoiesis in a chronic myelogenous leukemia patient after autologous transplant with peripheral blood Philadelphia\u2010negative haemopoietic cells","volume":"13","author":"Carella AM","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.11.4770.bloodjournal87114770"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70501-3"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb02187.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1055\/s-0038-1657648","article-title":"Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines","volume":"78","author":"Yang M","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9083"},{"key":"e_1_2_1_22_2","first-page":"256a","article-title":"Clinical pharmacokinetics and pharmacodynamics of STI571 in a phase I trial in chronic myelogenous leukemia (CML) patients","volume":"41","author":"Peng BHM","year":"2000","journal-title":"AACR Proc"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.10215","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.10215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T14:18:33Z","timestamp":1700317113000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.10215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,30]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["10.1002\/ajh.10215"],"URL":"https:\/\/doi.org\/10.1002\/ajh.10215","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,30]]}}}